Differences in cellular responses to mitogens in arterial smooth muscle cells derived from patients with moyamoya disease

Stroke

Volumn 29, Issue 6, 1998, Pages 1188-1193

  Yamamoto, Mari ^a   Aoyagi, Masaru ^a,b   Fukai, Naomi ^a   Matsushima, Yoshiharu ^b   Yamamoto, Kiyotaka ^a  

^a TOKYO METROPOLITAN INSTITUTE OF GERONTOLOGY   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Cytokines growth factors; Moyamoya disease; Muscle, smooth

Indexed keywords

CYTOKINE; INTERLEUKIN 1BETA; MITOGENIC AGENT; PLATELET DERIVED GROWTH FACTOR AA; PLATELET DERIVED GROWTH FACTOR BB; SCATTER FACTOR;

ARTERY INTIMA PROLIFERATION; ARTICLE; CELL MIGRATION; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DNA SYNTHESIS; FEMALE; HUMAN; HUMAN CELL; INFLAMMATORY CELL; MALE; MOYAMOYA DISEASE; PRIORITY JOURNAL; SMOOTH MUSCLE FIBER;

EID: 0031750240     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.29.6.1188     Document Type: Article

References (55)

1. Kudo T. Spontaneous occlusion of the circle of Willis: a disease apparently confined to Japanese. Neurology. 1968;18:485-496.
2. Nishimoto A, Takeuchi S. Abnormal cerebrovascular network related to the internal carotid arteries. J Neurosurg. 1968;29:255-260.
3. Suzuki J, Kodama N. Moyamoya disease: a review. Stroke. 1983;14: 104-109.
4. livanainen M, Vuolio M, Halonen V. Occlusive disease of intracranial main arteries with collateral networks (moyamoya disease) in adults. Acta Neurol Scand. 1973;49:307-322.
5. Lee MLK, Cheung EMT. Moyamoya disease as a cause of subarachnoid hemorrhage in Chinese. Brain. 1973;96:623-628.
6. Kitahara T, Ariga N, Yamaura A, Makino H, Maki Y. Familial occurrence of moyamoya disease: report of three Japanese families. J Neurol Neurosurg Psychiatry. 1979;42:208-214.
7. Houkin K, Tanaka N, Takahashi A, Kamiyama H, Abe H, Kajii N. Familial occurrence of moyamoya disease: magnetic resonance angiography as a screening test for high-risk subjects. Childs Nerv Syst. 1994;10:421-425.
8. Haltia M, Iivanainen M, Majuri H, Puranen M. Spontaneous occlusion of the circle of Willis (moyamoya syndrome). Clin Neuropathol (Berl). 1982;1:11-22.
9. Yamashita M, Oka K, Tanaka K. Histopathology of the brain vascular network in moyamoya disease. Stroke. 1983;14:50-58.
10. Hosoda Y. Pathology of so-called 'spontaneous occlusion of the circle of Willis.' Pathol Annu. 1984;19:221-244.
11. Takebayashi S, Matsuo K, Kaneko M. Ultrastructural studies of cerebral arteries and collateral vessels in moyamoya disease. Stroke. 1984;15: 728-732.
12. Halley SE, White WB, Ramsby GR, Voytovich AE. Renovascular hypertension in moyamoya syndrome: therapeutic response to percutaneous transluminal angioplasty. Am J Hypertens. 1988;1:348-352.
13. Aoyagi M, Fukai N, Yamamoto M, Nakagawa K, Matsushima Y, Yamamoto K. Early development of intimal thickening in superficial temporal arteries in patients with moyamoya disease. Stroke. 1996;7: 1750-1754.
14. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362:801-809.
15. Aoyagi M, Fukai N, Sakamoto H, Shinkai T, Matsushima Y, Yamamoto M, Yamamoto K. Altered cellular responses to serum mitogens, including platelet-derived growth factor, in cultured smooth muscle cells derived from arteries of patients with moyamoya disease. J Cell Physiol. 1991; 147:191-198.
16. 125I-PDGF binding and down-regulation of PDGF receptor in arterial smooth muscle cells derived from patients with moyamoya disease. J Cell Physiol. 1993;154:281-288.
17. Hoshimaru M, Takahashi JA, Kikuchi H, Nagata I, Hatanaka M. Possible roles of basic fibroblast growth factor in the pathogenesis of moyamoya disease: an immunohistochemical study. J Neurosurg. 1991;75:267-270.
18. Takahashi A, Sawamura Y, Houkin K, Kamiyama H, Abe H. The cerebrospinal fluid in patients with moyamoya disease (spontaneous occlusion of the circle of Willis) contains high level of basic fibroblast growth factor. Neurosci Lett. 1993;160:214-216.
19. Yoshimoto T, Houkin K, Takahashi A, Abe H. Angiogenic factors in moyamoya disease. Stroke. 1996;27:2160-2165.
20. Heldin C-H, Westermark B. Platelet-derived growth factor: mechanism of action and possible in vivo function. Cell Regul. 1990;1:555-566.
21. Hart CE, Forstrom JW, Kelly JD, Seifert RA, Smith RA, Ross R, Murray MJ, Bowen-Pope DF. Two classes of PDGF receptor recognize different isoforms of PDGF. Science. 1988;240:1529-1531.
22. Hosang M, Rouge M, Wipf B, Eggimann B, Kaufmann F, Hunziker W. Both homodimeric isoforms of PDGF (AA and BB) have mitogenic and chemotactic activity and stimulate phosphoinositol turnover. J Cell Physiol. 1989;140:558-564.
23. Libby P, Warner SJC, Salmon RN, Birinyi LK. Production of platelet-derived growth factor-like mitogen by smooth-muscle cells from human atheroma. N Engl J Med. 1988;318:1493-1498.
24. Sjölund M, Hedin U, Sejersen T, Heldin C-H, Thyberg J. Arterial smooth muscle cells express platelet-derived growth factor (PDGF) A chain mRNA, secrete a PDGF-like mitogen, and bind exogenous PDGF in a phenotype- and growth state-dependent manner. J Cell Biol. 1988;106: 403-413.
25. Klagsbrun M. The fibroblast growth factor family: structural and biological properties. Prog Growth Factor Res. 1989;1:207-235.
26. Masuda J, Ogata J, Yutani C. Smooth muscle cell proliferation and localization of macrophages and T cells in the occlusive intracranial major arteries in moyamoya disease. Stroke. 1993;24:1960-1967.
27. Hansson GK, Holm J. Interferon-γ inhibits arterial stenosis after injury. Circulation. 1991;84:1266-1272.
28. Dower SK, Sims JE, Cerretti DP, Bird TA. The interleukin-1 system: receptors, ligands and signals. Mol Biol Immunol. 1992;51:33-64.
29. Bendeck MP, Zempo N, Clowes AW, Galardy RE, Reidy MA. Smooth muscle cell migration and matrix metalloproteinases expression after arterial injury in the rat. Circ Res. 1994;75:539-545.
30. Fukai N, Aoyagi M, Yamamoto M, Sakamoto H, Ogami K, Matsushima Y, Yamamoto K. Human arterial smooth muscle cell strains derived from patients with moyamoya disease: changes in biological characteristics and proliferative response during cellular aging in vitro. Mech Ageing Dev. 1994;75:21-33.
31. Beasley D, Schwartz JH, Brenner BM. Interleukin 1 induces prolonged L-arginine-dependent cyclic guanosine monophosphate and nitrite production in rat vascular smooth muscle cells. J Clin Invest. 1991;87: 602-608.
32. Junquero DC, Scott-Burden T, Schini VB, Vanhoutte PM Inhibition of cytokine-induced nitric oxide production by transforming growth factor-β1 in human smooth muscle cells. J Physiol. 1992;454:451-465.
33. Fukuo K, Inoue T, Morimoto S, Nakahashi T, Yasuda O, Kitano S. Nitric oxide mediates cytotoxicity and basic fibroblast growth factor release in cultured vascular smooth muscle cells: a possible mechanism of neovascularization in atherosclerotic plaques. J Clin Invest. 1995;95:669-676.
34. 1 receptors. J Clin Invest. 1995;96:141-149.
35. Ross R. Platelet-derived growth factor. Lancet. 1989;1:1179-1182.
36. Majack RA, Majesky MW, Goodman LV. Role of PDGF-A expression in the control of vascular smooth muscle cell growth by transforming growth factor-β. J Cell Biol. 1990;111:239-247.
37. Koyama N, Morisaki N, Saito Y, Yoshida S. Regulatory effects of platelet-derived growth factor-AA homodimer on migration of vascular smooth muscle cells. J Biol Chem. 1992;267:22806-22812.
38. Koyama N, Hart CE, Clowes AW. Different functions of the platelet-derived growth factor-α and -β receptors for the migration and proliferation of cultured baboon smooth muscle cells Circ Res. 1994;75: 682-691.
39. Aoyagi M, Yamamoto M, Azuma H, Nagashima G, Niimi Y, Tamaki M, Hirakawa K, Yamamoto K. Immunolocalization of matrix metalloproteinases in rabbit carotid arteries after balloon denudation. Histochem Cell Biol. 1998;109:97-102.
40. Li Z, Li L, Zielke HR, Cheng L, Xiao R, Crow MT, Stetler-Stevenson WG, Froehlich J, Lakatta EG. Increased expression of 72-kd type IV collagenase (MMP-2) in human aortic atherosclerotic lesions Am J Pathol. 1996;148:121-128.
41. Lindner V, Reidy MA. Expression of basic growth factor and its receptor by smooth muscle cells and endothelium in injured rat arteries Circ Res. 1993;73:589-595.
42. Reidy MA. Neointimal proliferation: the role of basic FGF on vascular smooth muscle cell proliferation. Thromb Haemost. 1993;70:172-176.
43. Libby P, Warner SJC, Friedman GB. Interleukin 1: a mitogen for human vascular smooth muscle cells that induces the release of growth-inhibitory prostanoids. J Clin Invest. 1988;81:487-498.
44. Libby P, Hansson GK. Biology of disease: involvement of the immune system in human atherogenesis: current knowledge and unanswered questions. Lab Invest. 1991;64:5-15.
45. Dinarello CA. The biology of interleukin-1. Mol Biol Immunol. 1992; 51:1-32.
46. Schini VB, Junquero DC, Scott-Burden T, Vanhoutte PM. Interleukin-1β induces the production of an L-arginine-derived relaxing factor from cultured smooth muscle cells from rat aorta. Biochem Biophys Res Commun. 1991;176:114-121.
47. Cornwell TL, Arnold E, Boerth NJ, Lincoln TM. Inhibition of smooth muscle cell growth by nitric oxide and activation of cAMP-dependent protein kinase by cGMP. Am J Physiol. 1994;267:C1405-C1413.
48. Sarkar R, Meinberg EG, Stanley JC, Gordon D, Webb RC. Nitric oxide reversibly inhibits the migration of cultured vascular smooth muscle cells. Circ Res. 1996;78:225-230.
49. Beasley D, McGuiggin M. Interleukin 1 activates soluble guanylate cyclase in human vascular smooth muscle cells through a novel nitric oxide-independent pathway. J Exp Med. 1994;179:71-80.
50. Geng Y-J, Wu Q, Muszynski M, Hansson GK, Libby P. Apoptosis of vascular smooth muscle cells induced by in vitro stimulation with interferon-γ, tumor necrosis factor-α, and interleukin-1β. Arterioscler Thromb Vasc Biol. 1996;16:19-27.
51. Raines EW, Dower SK, Ross R. Interleukin-1 mitogenic activity for fibroblasts and smooth muscle cells is due to PDGF-AA. Science. 1989; 243:393-396.
52. Aoyagi M, Ogami K, Matsushima Y, Shikata M, Yamamoto M, Yamamoto K. Human leukocyte antigen in patients with moyamoya disease. Stroke. 1995;26:415-417.
53. Bamforth SD, Lightman SL, Greenwood J. Interleukin-1β-induced disruption of the retinal vascular barrier of the central nervous system is mediated through leukocyte recruitment and histamine Am J Pathol. 1997;150:329-340.
54. Lazarous DF, Shou M, Scheinowitz M, Hodge E, Thirumurti V, Kitsiou AN, Stiber JA, Lobo AD, Hunsberger S, Guetta E, Epstein SE, Unger EF. Comparative effects of basic growth factor and vascular endothelial growth factor on coronary collateral development and the arterial response to injury. Circulation. 1996;94:1074-1082.
55. Li J, Perrella MA, Tsai J-C, Yet S-F, Hsieh C-M, Yoshizumi M, Patterson C, Endege WO, Zhou F, Lee M-E. Induction of vascular endothelial growth factor gene expression by interleukin-1β in rat aortic smooth muscle cells. J Biol Chem. 1995;270:308-312.